Communiqués Recordati

Actions

REC

IT0003828271

Produits pharmaceutiques

Marché Fermé - Borsa Italiana 17:45:00 14/08/2026			Après clôture 19:46:09
52,50 ^EUR	-0,57%		52,52	+0,05%

11/08	Milan en tête en Europe ; WIIT s'illustre sur le Mid-Cap	AN
11/08	Futures prudents ; focus sur l'inflation américaine	AN

Communiqués

28/07	RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%	GL
16/06	RECORDATI CELEBRATES ITS FIRST 100 YEARS AT TRIENNALE MILANO WITH AN EXHIBITION REVEALING OBJECTS AND IMAGES FROM ITS HISTORICAL ARCHIVE FOR THE FIRST TIME	GL
14/05	Recordati : First Quarter Report 2026	PU
12/05	RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%	GL
30/04	RECORDATI: SUMMARY REPORT OF THE VOTES – ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS 29.04.2026	PU
30/04	Recordati : 30th April 2026 - Summary report of the votes	PU
01/04	Recordati : 1st April 2026 - Report of the Board of Statutory Auditors to the Shareholders’ Meeting	PU
01/04	Recordati : 1 April 2026 - Financial Statements of Recordati S.p.A. at 31 December 2025 and related Report of the Auditing Firm	PU
27/03	RECORDATI: PUBLICATION OF DOCUMENTS RELATING TO THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF THE SHAREHOLDERS CALLED FOR 29.04.2026	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 1 on the agenda of the Shareholders’ Meeting 29.04.2026 (extraordinary session) – Delegation of authority to the BoDs pursuant to artt 2420-ter and 2443 of the Italian Civil Code	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 5 on the agenda (ordinary session) - Authorization to the purchase and disposal of treasury stock	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 4 on the agenda (ordinary session) - Approval of the “2026-2028 Performance Shares Plan”	PU
27/03	Recordati : 27 March 2026 - Directors' Report on item 3 on the agenda (ordinary session) - Report on the remuneration policy and the remuneration paid	PU
20/03	Recordati : 20th March 2026 - Call to an Ordinary and Extraordinary General Meeting of the Shareholders 29.04.2026	PU
20/03	Recordati : 20th March 2026 - Directors' Report on item 2 on the agenda (ordinary session) – Appointment of the Board of Statutory Auditors	PU
17/02	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%	GL
17/02	RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE 11.8%, EBITDA 14.5%, ADJUSTED NET INCOME 14.5%	PU
29/01	RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA	GL
14/01	Recordati : 14 January 2026 - J.P. Morgan Healthcare Conference Presentation	PU
14/11	Recordati : First nine months 2025	PU
11/11	RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION	GL
11/11	Recordati : Directors' report on the distribution of an interim dividend and interim financial statements at 30 June 2025	PU
23/10/25	RECORDATI APPOINTS MIKE MCCLELLAN AS NEW CHIEF FINANCIAL OFFICER	GL
21/10/25	Recordati Launches 12th Edition of Arrigo Recordati Prize to Support Research in Paediatric Oncology	GL
31/07/25	RECORDATI: PUBLICATION OF THE MINUTES OF THE BOARD OF DIRECTORS’ MEETING HELD ON 29 JULY 2025	PU